HPV
SCG Cell Therapy to Begin Phase I Trial of T-Cell Receptor Therapy in HPV-Associated Solid Tumors
The FDA's clearance of its IND allows the firm to take a second T-cell receptor therapy into clinical trials.
Researchers Highlight Progress in Head and Neck Cancer MRD at ASCO, but Results Remain Preliminary
Premium
Clinicians said that residual disease tests could be of great benefit to this population, but advancing technologies will still have to prove themselves.
The firm's long-term goal is to develop targeted cancer vaccines for patients at every stage of disease, including pre-cancer.
Naveris, MSK Begin Phase II Clinical Study in MRD-Positive Head and Neck Cancer
The company's blood-based NavDx assay will be used to identify patients with molecular relapse who are eligible for additional treatment.
Nykode Therapeutics Evaluating Cancer Vaccine With Tecentriq in HPV16-Positive Cervical Cancer
The double-blind trial will determine whether the cancer vaccine VB10.16 alone or combined with Tecentriq is more effective.
Nov 30, 2023